FCH
PACB icon

Freestone Capital Holdings’s Pacific Biosciences PACB Stock Holding History

Freestone Capital Holdings’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,700
Closed -$269K – 436
2021
Q2 		$269K Hold
7,700
– – 0.01% 364
2021
Q1 		$256K Hold
7,700
– – 0.01% 351
2020
Q4 		$200K Hold
7,700
– – 0.01% 348
2020
Q3 		$76K Buy
+7,700
New +$44.3K 0.01% 427

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Freestone Capital Holdings's PACB Position: Q3 2021 in Review

Freestone Capital Holdings sold out of Pacific Biosciences (PACB) in Q3 2021, closing a stake of 7,700 shares — an estimated $269K sold.

Freestone Capital Holdings first reported a position in PACB in Q3 2020 and held it in 4 quarters. The position peaked at $269K in Q2 2021. 246 funds tracked by Wall St. Rank hold PACB as of Q3 2021.

  • Freestone Capital Holdings reported no remaining Pacific Biosciences position as of Q3 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 7,700 Pacific Biosciences shares in Q3 2021, an estimated $269K.
  • Freestone Capital Holdings first reported a position in Pacific Biosciences in Q3 2020 and held it in 4 quarters.
  • Freestone Capital Holdings's Pacific Biosciences position peaked at $269K in Q2 2021.
  • 246 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2021.

Based on Freestone Capital Holdings's 13F filing for Q3 2021, filed 15 Nov 2021.